Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase®

Thi Thu Ha Nguyen (), Anne Roussin, Vanessa Rousseau, Jean-Louis Montastruc and François Montastruc
Additional contact information
Thi Thu Ha Nguyen: Université Paul Sabatier
Anne Roussin: Université Paul Sabatier
Vanessa Rousseau: Université Paul Sabatier
Jean-Louis Montastruc: Université Paul Sabatier
François Montastruc: Université Paul Sabatier

Drug Safety, 2018, vol. 41, issue 11, No 9, 1087-1096

Abstract: Abstract Background The association between antidepressant exposure and type 2 diabetes mellitus is still debated. Moreover, the pharmacological mechanisms remain unknown. Objective The objective of this study was to investigate this putative relationship with the role of antidepressant pharmacological targets using the ‘pharmacoepidemiological–pharmacodynamic’ method. Methods First, we performed case/non-case analyses in VigiBase® (the World Health Organization international database of suspected adverse drug reactions) to examine a signal of increased type 2 diabetes reporting (expressed as the reporting odds ratio and its 95% confidence interval) for antidepressants in general; examine and rank type 2 diabetes signals between the different pharmacological classes of antidepressants and the different antidepressants (58 in total). Second, we performed linear regression analyses to explore the association between the type 2 diabetes signal ranked between antidepressants and their binding affinities for nine targets (serotonin, norepinephrine, dopamine transporters, 5-HT2C serotonin, D2 dopamine, α1, α2 adrenergic, M3 muscarinic and H1 histamine receptors). Results A significant type 2 diabetes signal was found for antidepressants in general, three classes of antidepressants (tricyclic antidepressants, serotonin reuptake inhibitors and “other” antidepressants) and 15 individual antidepressants in particular. Among the antidepressants, three serotonin reuptake inhibitors [escitalopram (adjusted reporting odds ratio 1.15 [1.07–1.25]), paroxetine (1.15 [1.07–1.23]), sertraline (1.23 [1.17–1.31])] and three “other” antidepressants [duloxetine (1.15 [1.07–1.23]), trazodone (1.20 [1.09–1.32]), venlafaxine (1.15 [1.08–1.23])] were the antidepressants most frequently reported with type 2 diabetes. We found a significant correlation between the type 2 diabetes signal and serotonin transporter affinity (slope = 0.14 [0.06–0.23], p = 0.003, R2 = 0.43) but not the other targets. Conclusion The present study suggests a potential role for serotonin transporter in antidepressant-induced type 2 diabetes.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0693-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:41:y:2018:i:11:d:10.1007_s40264-018-0693-8

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0693-8

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().